Company news
Aura Biosciences, Inc. (NASDAQ:AURA) news
Aura Biosciences, Inc. news releases on 6ix. Latest, Sep 2, 2026: Aura Biosciences to Participate in Upcoming Investor Conference
Press releases & updates
Aura Biosciences to Participate in Upcoming Investor Conference
September 2, 2026
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 11, 2026
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
July 8, 2026
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
June 1, 2026
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
May 20, 2026
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 19, 2026
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
May 11, 2026
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 5, 2026
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
May 4, 2026
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 4, 2026
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion
May 4, 2026
Auranova Announces Closing of Private Placement of Flow-Through Shares
April 7, 2026
Auranova Resources and Kenorland Minerals Commence Spring Drill Program at South Uchi Project
April 1, 2026
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
March 29, 2026
Auranova Resources and Kenorland Minerals Announce Upcoming 2026 Spring Drill Program at The South Uchi Project, Ontario
March 18, 2026
Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference
November 24, 2025
Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights
November 13, 2025
Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights
August 13, 2025
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
May 15, 2025
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants
May 15, 2025
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights
May 15, 2025
Aura Biosciences to Participate in Upcoming Investor Conferences
May 1, 2025
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
April 2, 2025
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
March 24, 2025
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress
March 24, 2025
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress
March 3, 2025
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
November 25, 2024
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
November 11, 2024
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
October 16, 2024
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
September 11, 2024
Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024
September 2, 2024
Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting
August 25, 2024
Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights
August 7, 2024
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024
May 22, 2024
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
May 8, 2024
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 26, 2024
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
December 6, 2023
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
November 8, 2023
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
November 5, 2023
Aura Biosciences Announces Proposed Public Offering of Common Stock
November 5, 2023
Aura Biosciences Announces Pricing of Public Offering of Common Stock
November 5, 2023
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
October 30, 2023
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
October 1, 2023
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
August 8, 2023
Aura Biosciences to Participate in the JMP Securities Life Sciences Conference
May 11, 2023
Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
May 10, 2023
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights
March 14, 2023
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration
February 15, 2023